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Abstract: Nanotheranostics combine the use of nanomaterials and biologically active compounds to achieve 
diagnosis and treatment at the same time. To date, severe limitations compromise the use of nanotheranostic 
systems as potent nanomaterials are often incompatible with potent biomolecules. Herein we emphasize how 
a novel type of polymersome clusters loaded with active molecules can be optimized to obtain an efficient 
nanotheranostic platform. Polymersomes loaded with enzymes and specific dyes, respectively and exposing 
complementary DNA strands at their external surface formed clusters by means of DNA hybridization. We de-
scribe factors at the molecular level and other conditions that need to be optimized at each step of the cluster 
formation to favor theranostic efficiency.
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1. Introduction
Theranostics is a field of medicine that combines both therapy 
and diagnosis to reduce multi-step procedures thereby improving 
patient care and enhancing chances of cure. The therapeutic part 
of theranostic systems is usually achieved via release of bioac-
tive compounds, hyperthermia or reactive organic species (ROS) 
production, while the diagnosis part mostly involves imaging 
methods like MRI, fluorescence or ultrasound.[1] Theranostic 
systems are often based on nanomaterials whose small size and 
interesting intrinsic properties make them particularly suited for 
such dual applications. For example, inorganic nanoparticles like 
SPION or quantum dots possess the unique advantage of being 
intrinsic imaging agents but their potential toxicity limits applica-
tion.[1,2] On the other hand, lipid- or polymer-based micelles are 
potent support materials as they are non-toxic and can integrate 
hydrophobic therapeutic/imaging agents within their hydropho-
bic core.[1,3] However, increasing the range of applications cru-
cially depends on improving the loading capacity for hydrophilic 
active compounds which cannot be achieved by using micelles. 
Of particular interest are soft nanocompartments, i.e. liposomes 
and polymersomes as they consist of an amphiphilic membrane 
enclosing an aqueous cavity and therefore allow for integrating 
hydrophobic compounds within their membrane and loading their 
cavity with hydrophilic compounds.[4–6] In addition, the external 
surface of nanocompartments can be functionalized to gain tar-
geting properties, especially in the case of polymersomes as they 
benefit from the sheer endless chemical versatility of polymers.[4] 
As polymersomes have an increased mechanical stability com-
pared to liposomes, they appear to be ideal materials for building 
a non-toxic nanotheranostic platform, adaptable to different ap-
plications.[4,5] The architecture of nanothernostic systems usually 
comprises assemblies simultaneously containing therapeutic and 
imaging compounds, for example via co-encapsulation of both 
agents inside soft-nanocompartments.[7] However, co-encapsu-
lation can be detrimental for sensitive compounds or negatively 
affect the encapsulation efficiency of active agents. These serious 
drawbacks can be overcome by another type of nanotheranostic 
architecture based on super-assemblies: the combination of dis-
tinct nanomaterials that each are equipped with either the thera-
peutic or the imaging function. However, most super-assemblies 
are composed of inorganic nanoparticles and/or held together by 
weak, non-covalent interactions that compromise their efficacy, 
especially under physiological conditions where dissociation of 
the assembly is likely to occur.[8–10] To overcome such constraints, 
we developed a super-assembly composed of two different types 
of polymersomes, one bearing the therapeutic function while the 
other one enables imaging, tethered together by hybridization of 
complementary DNA strands exposed on the respective surfaces 
(Fig. 1a).[11,12] In addition, the ssDNA not involved in tether-
ing served to promote attachment to cells expressing scavenger 
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2. Optimization of Polymersome Clusters for Theranostic 
Applications
2.1 Nanotheranostic Polymersome Cluster Formation
Nanotheranostic polymersome clusters are formed during a 
four-step procedure: 1) thin polymer film formation, 2) polymer-
some formation by self-assembly, 3) ssDNA coupling to the exter-
nal surface of polymersomes and 4) clustering of loaded polymer-
somes into super-assemblies (Fig. 1b). Each of these steps has to 
be optimized in different ways for a given application. To prepare 
polymersomes by the film-rehydration method, a solution of am-
phiphilic copolymers is dried in a round-bottom flask to form a 
thin film of polymer which is then rehydrated with an aqueous so-
lution containing active compounds (enzymes or imaging agents) 
that get encapsulated while the polymer film detaches from the 
flask and self-assembles into nano-sized assemblies. [11] The thera-
peutic and imaging polymersomes were prepared in parallel, each 
under specific conditions, before being surface-functionalized 
with complementary ssDNA. After removal of unbound ssDNA 
and non-encapsulated active compounds, both kinds of polymer-
some were mixed together to induce DNA hybridization for clus-
ter formation.[11–13]
2.2 Optimization of Polymersome Formation
When selecting a copolymer, requirements in terms of the 
self-assembly process that should yield polymersomes and pro-
vide an enhanced functionalization potential have to be taken 
into account. In this respect, we used a diblock copolymer poly 
(dimethylsiloxane)-block-poly(2-methyloxazoline) (PMOXA-b-
receptors, e.g. epithelial cells.[13] In view of the enzyme (Dopa 
Decarboxylase, DCC) encapsulated into the therapeutic polymer-
somes, our system is geared towards applications in the treatment 
of atherosclerosis in that polymersome clusters could attach to 
atherosclerotic lesions, produce and deliver on-site a therapeu-
tic compound (dopamine), while at the same time, the imaging 
compartment serves to follow the lesions’ dynamics by the imag-
ing modality.[11] In general, the imaging property of theranostic 
systems is achieved via encapsulation of fluorescent dyes or MRI 
agents within the ‘imaging’ polymersome.[1,4,5,11] The communi-
cation between the external environment and the polymersome 
cavity where enzymes were located, was accomplished by per-
meabilization of the polymer membrane via incorporation of pore 
forming proteins (Outer membrane protein F, OmpF).[14,15] This 
way, substrates reached the encapsulated enzymes and the result-
ing therapeutic product diffused out of the polymersomes to act 
on nearby cells.[11] These polymersome clusters offer great advan-
tages such as robustness, stability in physiological environments, 
and in vivo, non-toxicity, efficient dual-functionality (due to the 
segregation of the therapeutic and imaging compounds), and can 
be easily modified to achieve desired applications.[4,11,13] To ac-
commodate the therapeutic enzymes or imaging agents chosen in 
view of a specific application, several steps of the polymersome 
cluster formation need to be optimized. Here, we explain how the 
optimization steps were achieved for polymersome clusters at a 
molecular level (Fig. 1b), in respect to the conditions required 
to preserve the nanocompartments’ architecture, to support their 
clustering and ultimately obtain the dual-functionality required 
for theranostic applications.
Fig. 1. Nanotheranostic polymer-
some clusters: (a) architecture 
providing therapeutic and di-
agnostic features (b) four steps 
involved in nanocluster formation 
with corresponding optimization 
possibilities. 
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with dibenzocyclooctyne DBCO-functionalized ssDNA that re-
acts with azide groups exposed by the polymersome surface.[12] 
To preserve the functionality of encapsulated active compounds, 
the surface functionalization of polymersomes with ssDNA was 
performed at low temperature (4 °C).[11] To facilitate the SPAAC 
reaction, ssDNA sequences should be chosen such as to avoid the 
formation of secondary structures, e.g. hairpins that might inter-
fere with the availability of the DBCO group. Besides, the length 
and sequence of the ssDNA were tailored to promote cell attach-
ment of clusters.[11,13] After the hybridization of DNA between 
‘complementary’ polymersomes, which induced cluster for-
mation (see below),[12] around 80% of the total number of ss-
DNA remained exposed at the surface of the clusters. These 
residual single-stranded DNAs served for cell attachment as 
their negative charge exhibited a strong affinity for scavenger 
receptors that are highly expressed on distinct cell types.[19,20]
For the last step of cluster formation, polymersomes loaded 
with enzyme and dye, respectively, were mixed together and 
the hybridization of the complementary ssDNA resulted in their 
tethering into super-assemblies. In order to avoid aggregation 
and control the size of polymersome clusters, diverse factors 
have been varied: the ssDNA hybridization conditions (time and 
temperature), the concentration and the ratio of polymersomes 
with regard to the number of ssDNA present on each type of 
polymersome.[11–13] For example, when one type of polymer-
some exposed significantly higher numbers of ssDNA on its 
surface (around 100–200 ssDNA/polymersome) compared to 
the other type of polymersome (20–30 ssDNA/polymersome), 
the formation of clusters at 20 °C was still possible because 
the probability of annealing was still high enough due to high 
surface density of at least one kind of ssDNA strand.[11] In con-
trast, when both polymersomes have a low surface density of 
ssDNA, no clusters were formed. On the other hand, if both 
types of polymersomes expose high densities of ssDNA they 
tend to aggregate, which was avoided by diluting the polymer-
some solutions and/or decreasing the temperature (no cluster 
formation was observed at 4 °C).[11] Taken together, the optimi-
zation of the surface density of ssDNA/polymersome and the 
conditions for promoting hybridization have to be specifically 
PDMS) known to generate polymersomes by self-assembly in di-
lute aqueous solutions.[11,16] The ability of the copolymer to read-
ily self-assemble into polymersomes is determined by the hydro-
philic-to-hydrophobic ratio of the respective blocks. We selected 



















) prior to 
the thin film formation. To facilitate surface functionalization of 
formed polymersomes while preserving the membrane integrity, 
the fraction of azide-copolymer in the polymer mixture was var-
ied from 1 to 100 %.[11–13] In addition, the total concentration of 
polymer used for film formation was varied to obtain concentrated 
polymersome solutions but avoid aggregation.[11] Here, we em-
phasize that almost five-times more polymersomes were formed 
at a polymer concentration of 10 mg/mL compared to 2 mg/mL 
(Table 1). It is essential to achieve high polymersome concen-
trations for an improved therapeutic and imaging efficiency, es-
pecially since after both kinds of polymersome are prepared in 
parallel, they are mixed together (in 1:1 ratio) to form the clusters, 
resulting in halved respective concentrations.[11] Taken together, 
the choice of the copolymer and the accessibility of azide groups 
are crucial and have considerable effects on the rest of the cluster 
formation procedure. 
In the second step -the polymersome formation via the film 
rehydration method, it was critical to use a short copolymer not 
only for self-assembly to occur very fast (less than one minute at 
room temperature) and at a broad range of temperatures (4 °C – 
>25 °C) but also to achieve protein insertion into the membrane. [11] 
Depending on the specificity of the enzymes and dyes to be encap-
sulated (solubility, stability), the conditions of the self-assembly 
process have to be adapted to preserve the functionality of the ac-
tive compounds, which is critical to achieve efficient theranostic 
response. Therefore, thanks to the short length of our polymer, the 
conditions of vesicle formation (3 hours at 4 °C) had been tuned to 
support the encapsulation of compounds (enzymes, proteins, fluo-
rescent dyes) without affecting their properties. The encapsula-
tion via film rehydration is a statistical process which implies that 
the amount of encapsulated compound is not linearly correlated 
with the compound concentration of the rehydration solution and 
therefore, the encapsulation efficiency often remains relatively 
low.[17] However, the limited compound encapsulation (enzymes, 
imaging agents) was not an issue as we selected compounds with 
efficient therapeutic/imaging properties and performed their en-
capsulation under adapted conditions.[11,16,18]
2.3 Optimization of Cluster Formation
The third step of polymersome cluster formation consists of 
grafting complementary ssDNA onto the surface of the differ-
ent polymersomes. We used azide-alkyne cycloaddition (SPAAC) 
Fig. 2. a) Confocal laser scanning 
microscopy images of model 
clusters composed of two kinds 
of polymersomes encapsulating 
fluorescent dyes (Dy-633 or Atto-
488) reveal the co-localization of 
both types of fluorescent poly-
mersomes within clusters and 
their attachment to the surface of 
scavenger receptor expressing 
HEK293T cells (scale bar = 20 
µm). b) Dynamic light scattering 
(DLS) showing the size of nano-
theranostic polymersome clusters 
after one year of storage in PBS 
at 4 °C.
Table 1. Number of polymersomes per mL obtained from the rehydration 
of 600 µL of PDMS22-b-PMOXA8 with PBS for 12 h at room tempera-
ture, at different concentrations.
Concentration  
of polymer
2 mg/mL 10 mg/mL
Number of  
polymersomes
4.8 × 1011 /mL 2.1 × 1012 /mL
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adjusted to avoid aggregation and obtain clusters with a desired 
size.[11–13]
Once the colloidal stability and controlled architecture of the 
clusters had been achieved, their dual-functionality was evaluat-
ed: by encapsulation of Dopa Decarboxylase (DDC) in the thera-
peutic polymersomes and Atto-488 dye in the imaging ones, the 
clusters successfully produced dopamine in sufficient amounts to 
induce a cell response while generating a fluorescent signal for 
cell imaging.[11] In addition, as illustrated in Fig. 2, nanotheranos-
tic clusters dock onto cell membranes via interactions of ssDNA 
with scavenger receptors, further emphasizing the applicability 
for cell-specific interactions (Fig. 2a) and are stable upon long-
term storage as clusters maintained their architecture and size 
(495 ± 212 nm) for more than a year after formation (Fig. 2b), 
which is another essential feature for translational applications.
3. Conclusions and Outlook
Based on the many possibilities of adaptation, the super-
assembly of DNA-linked polymersomes loaded with different 
active compounds (enzymes for therapeutic purposes and dyes 
for imaging) represents a nanotheranostic platform that can be 
tailored to specific applications. Being constructed in a modular 
manner, these clusters offer extensive flexibility by an association 
of different polymersomes that can be tuned by a straightforward 
change of the enzymes or the contrast agents to a large variety 
of pathological conditions. The stable architecture makes these 
nanosystems particularly suited for implementing this technology 
with additional modalities including targeting, responsiveness to 
pathological stimuli and synergistic therapies.
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